AU2006231617B2 - Crystal form of asenapine maleate - Google Patents

Crystal form of asenapine maleate Download PDF

Info

Publication number
AU2006231617B2
AU2006231617B2 AU2006231617A AU2006231617A AU2006231617B2 AU 2006231617 B2 AU2006231617 B2 AU 2006231617B2 AU 2006231617 A AU2006231617 A AU 2006231617A AU 2006231617 A AU2006231617 A AU 2006231617A AU 2006231617 B2 AU2006231617 B2 AU 2006231617B2
Authority
AU
Australia
Prior art keywords
oxepino
dibenz
pyrrole
tetrahydro
orthorhombic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2006231617A
Other languages
English (en)
Other versions
AU2006231617A1 (en
Inventor
Gerhardus Johannes Heeres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2006231617(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme BV
Publication of AU2006231617A1 publication Critical patent/AU2006231617A1/en
Application granted granted Critical
Publication of AU2006231617B2 publication Critical patent/AU2006231617B2/en
Assigned to MSD OSS B.V. reassignment MSD OSS B.V. Request to Amend Deed and Register Assignors: N.V. ORGANON
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Request to Amend Deed and Register Assignors: MSD OSS B.V.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
AU2006231617A 2005-04-07 2006-04-06 Crystal form of asenapine maleate Active AU2006231617B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05102742 2005-04-07
EP05102742.3 2005-04-07
EP05102969 2005-04-14
EP05102969.2 2005-04-14
PCT/EP2006/061408 WO2006106135A1 (en) 2005-04-07 2006-04-06 Crystal form of asenapine maleate

Publications (2)

Publication Number Publication Date
AU2006231617A1 AU2006231617A1 (en) 2006-10-12
AU2006231617B2 true AU2006231617B2 (en) 2010-06-03

Family

ID=36617328

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006231617A Active AU2006231617B2 (en) 2005-04-07 2006-04-06 Crystal form of asenapine maleate

Country Status (31)

Country Link
EP (2) EP1917267B1 (zh)
JP (1) JP5058151B2 (zh)
KR (1) KR101422843B1 (zh)
AR (1) AR056306A1 (zh)
AT (2) ATE418556T1 (zh)
AU (1) AU2006231617B2 (zh)
BR (1) BRPI0609741A8 (zh)
CA (1) CA2603509C (zh)
CY (2) CY1106902T1 (zh)
DE (2) DE602006000080T2 (zh)
DK (2) DK1710245T3 (zh)
DO (1) DOP2006000082A (zh)
ES (2) ES2293626T3 (zh)
GT (1) GT200600135A (zh)
HN (1) HN2006014095A (zh)
HR (1) HRP20070429T3 (zh)
IL (1) IL186355A (zh)
MX (1) MX2007012445A (zh)
MY (1) MY137969A (zh)
NO (1) NO340520B1 (zh)
NZ (1) NZ562124A (zh)
PE (1) PE20061311A1 (zh)
PL (2) PL1917267T3 (zh)
PT (2) PT1917267E (zh)
RS (1) RS50532B (zh)
RU (1) RU2405786C2 (zh)
SI (2) SI1710245T1 (zh)
SV (1) SV2006002473A (zh)
TW (1) TWI364423B (zh)
UY (1) UY29459A1 (zh)
WO (1) WO2006106135A1 (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080090892A1 (en) * 2006-10-06 2008-04-17 N.V. Organon Amorphous asenapine and processes for preparing same
MX2012000061A (es) * 2009-06-24 2012-06-01 Msd Oss Bv Formulaciones inyectables que contienen asenapina, y metodo de tratamiento usando las mismas.
WO2011159903A2 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
WO2012066565A2 (en) * 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) * 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524920A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Asenapine Hydrochloride Salt Forms
EP2524919A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
EP2524921A1 (en) 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
WO2012156676A1 (en) 2011-05-18 2012-11-22 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
JP6014656B2 (ja) * 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
WO2014017593A1 (ja) * 2012-07-26 2014-01-30 久光製薬株式会社 貼付剤及びその製造方法
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
US9597291B2 (en) 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
WO2017037718A1 (en) 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
EP3558275A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
ATE167057T1 (de) * 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
AU2418499A (en) * 1997-12-19 1999-07-12 Akzo Nobel N.V. Org-5222 in the treatment of depression
TWI327915B (en) * 2003-06-12 2010-08-01 Organon Nv Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight

Also Published As

Publication number Publication date
MX2007012445A (es) 2007-11-07
TWI364423B (en) 2012-05-21
MY137969A (en) 2009-04-30
JP5058151B2 (ja) 2012-10-24
SI1917267T1 (sl) 2009-04-30
DK1917267T3 (da) 2009-04-14
PE20061311A1 (es) 2007-02-09
WO2006106135A1 (en) 2006-10-12
DOP2006000082A (es) 2006-11-30
JP2008534656A (ja) 2008-08-28
NZ562124A (en) 2010-07-30
EP1710245A1 (en) 2006-10-11
BRPI0609741A2 (pt) 2010-04-27
BRPI0609741A8 (pt) 2018-03-13
ATE418556T1 (de) 2009-01-15
CY1108742T1 (el) 2014-04-09
KR101422843B1 (ko) 2014-07-24
ATE370954T1 (de) 2007-09-15
PL1710245T3 (pl) 2008-01-31
PT1710245E (pt) 2007-10-03
DE602006000080T2 (de) 2008-05-15
PT1917267E (pt) 2009-02-04
AU2006231617A1 (en) 2006-10-12
EP1917267B1 (en) 2008-12-24
RU2405786C2 (ru) 2010-12-10
IL186355A0 (en) 2008-01-20
SI1710245T1 (sl) 2007-12-31
CA2603509A1 (en) 2006-10-12
DE602006004463D1 (de) 2009-02-05
HN2006014095A (es) 2010-08-19
NO340520B1 (no) 2017-05-02
ES2293626T3 (es) 2008-03-16
KR20080005253A (ko) 2008-01-10
DE602006000080D1 (de) 2007-10-04
HRP20070429T3 (en) 2007-11-30
AR056306A1 (es) 2007-10-03
RU2007141198A (ru) 2009-05-20
DK1710245T3 (da) 2007-12-03
NO20075142L (no) 2007-11-05
SV2006002473A (es) 2009-11-24
CY1106902T1 (el) 2012-09-26
UY29459A1 (es) 2006-11-30
PL1917267T3 (pl) 2009-06-30
CA2603509C (en) 2013-12-03
IL186355A (en) 2016-05-31
GT200600135A (es) 2006-11-07
EP1917267A1 (en) 2008-05-07
ES2318742T3 (es) 2009-05-01
EP1710245B1 (en) 2007-08-22
TW200722428A (en) 2007-06-16
RS50532B (sr) 2010-05-07

Similar Documents

Publication Publication Date Title
AU2006231617B2 (en) Crystal form of asenapine maleate
US7741358B2 (en) Crystal form of asenapine maleate
CN1861604B (zh) 阿色纳品马来酸盐的晶型
AU2018259089B2 (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production
EP3647312B1 (en) Crystal form of deuterated azd9291, preparation method therefor, and use thereof
WO2012123325A1 (en) NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
EP1962600A2 (en) Metronidazole cocrystals and imipramine cocrystals
US20020173648A1 (en) Novel polymorphic forms of cipamfylline
CN114773211B (zh) 一种葡甲胺盐的晶型、其制备方法及应用
CN116041323A (zh) Sigma-1受体激动剂的酸式盐、其晶型及其制备方法和应用
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
KR20230035050A (ko) 옥타히드로티에노퀴놀린 화합물의 숙신산염 및 그 결정
WO2010123441A1 (en) Crystalline form of 4-amino-8-(2-fluoro-6-methoxy-phenyl)-n-propylcinnoline-3- carboxamide hydrogen sulphate, for treatment of anxiety disorders
KR20060073939A (ko) 비페프루녹스메실레이트(7-[4-([1,1'-비페닐]-3-일메틸)-1-피페라지닐]-2(3ｈ)-벤즈옥사졸론 모노메탄설포네이트)의 안정한 결정질형태

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)